Skip to content
  • Sunday, 26 July 2026
  • 2:10 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Johnson & Johnson’s Spravato Remission Data Takes Center Stage in Push for Treatment-Resistant Depression Growth
Laboratory Automation & Robotics

Johnson & Johnson’s Spravato Remission Data Takes Center Stage in Push for Treatment-Resistant Depression Growth

Lana Keisha Jul 19, 2026 0

A recent poster presentation at Psych Congress Elevate by Johnson & Johnson has placed esketamine nasal spray, marketed as Spravato,…

Read More
Pharmaceutical R&D

Johnson & Johnson Forecasts Accelerated Growth in 2026 Driven by New Psoriasis Treatment, Icotyde, and Robust Pharma Portfolio

Teuku Ryan Apr 16, 2026 0

Johnson & Johnson (J&J) has reported a strong start to 2026, exceeding analyst expectations with robust first-quarter earnings and revising…

Read More
Pharmaceutical R&D

Johnson & Johnson’s Icotyde Poised to Challenge AbbVie’s Skyrizi in Plaque Psoriasis Market

Teuku Ryan Mar 21, 2026 0

The landscape of plaque psoriasis treatment is on the cusp of a significant shift with the U.S. Food and Drug…

Read More
Discovery of Fam102a as a Dual Regulator in Bone Remodeling Offers New Pathways for Osteoporosis TreatmentEvogene, Systasy and LMU University Hospital Munich team up on AI-driven drug discovery for inflammatory diseasesDiabetes to MASH: the specimens behind GLP-1’s widening rosterNew Research Unveils Molecular Competition as Key Driver in Alzheimer’s Disease Progression
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ